Dipeptidyl Peptidase 4 Inhibitor, an Update / 임상당뇨병
Journal of Korean Diabetes
; : 91-96, 2021.
Article
in Ko
| WPRIM
| ID: wpr-918915
Responsible library:
WPRO
ABSTRACT
Dipeptidyl peptidase 4 (DPP4) inhibitors, one of the most prescribed second-line antidiabetic drugs in South Korea, have been available since 2006. Many studies focusing on the safety profiles of DPP4 inhibitors have been reported. DPP4 inhibitors were associated with a small increased incidence of acute pancreatitis in placebo-controlled trials, although most observational studies did not support this hypothesis. There were no significant differences in major cardiovascular events in a large prospective cardiovascular outcomes trial with DPP4 inhibitors, although a higher risk of hospitalization for heart failure was reported with saxagliptin. Additionally, the safety data of DPP4 inhibitors for diabetes management during the coronavirus disease-19 (COVID-19) pandemic have been provided recently.
Full text:
1
Index:
WPRIM
Type of study:
Clinical_trials
/
Observational_studies
Language:
Ko
Journal:
Journal of Korean Diabetes
Year:
2021
Type:
Article